Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2025
Reporting Period: Update on financial position as of September 30, 2025, and business developments for the remainder of 2025 and 2026.
Key Financial Metrics
Liquidity: Preliminary unaudited cash, cash equivalents, and marketable securities as of September 30, 2025, were approximately $615.9 million.
Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the quarter ended September 30, 2025.
Debt: The filing text does not provide specific values for outstanding debt or credit facilities.
Material Changes and Developments
This report primarily discloses a preliminary liquidity update and strategic milestones rather than historical financial performance changes. Key developments include:
- Bitopertin (GlyT1 Inhibitor): Accelerating activities for potential US approval and launch in late 2025 or early 2026, leveraging a Commissioner's National Priority Voucher (CNPV) to shorten FDA review to 1-2 months. Enrollment continues in the APOLLO confirmatory trial for erythropoietic protoporphyria.
- DISC-0974 (Anti-hemojuvelin Antibody): Initial Phase 2 data in anemia of myelofibrosis expected by year-end; topline data anticipated in 2026. A Phase 1b study in non-dialysis dependent chronic kidney disease showed mechanism engagement but variable hemoglobin effects, with full data to be shared at the 2025 ASN Kidney Week. A Phase 2 study in inflammatory bowel disease is planned for Q1 2026.
- DISC-3405 (Anti-TMPRSS6 Antibody): Topline Phase 2 data for polycythemia vera expected in 2026. A Phase 1b study in sickle cell disease is anticipated to initiate by year-end.
Guidance, Outlook, and Risks
Outlook: Management outlined near-term objectives to advance clinical programs and prepare for potential regulatory approvals. The company is assessing options for the DISC-0974 program based on full data analysis from recent studies.
Risks and Contingencies: The filing contains forward-looking statements regarding clinical trial timelines, regulatory approvals, and launch dates. Actual results may differ materially due to uncertainties in market conditions, clinical outcomes, and regulatory decisions. The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Verify the final audited cash position in the upcoming Form 10-Q for the quarter ended September 30, 2025, as the $615.9 million figure is preliminary and unaudited.
- Monitor the release of topline data for the APOLLO trial (bitopertin) and the Phase 2 myelofibrosis study (DISC-0974) expected in 2026.
- Review the full data presentation at the 2025 ASN Kidney Week regarding the DISC-0974 chronic kidney disease study to assess the commercial viability of that indication.
- Confirm the status of the FDA Commissioner's National Priority Voucher (CNPV) and its impact on the bitopertin review timeline.